Unicycive Therapeutics (NASDAQ:UNCY) Given New $15.00 Price Target at Benchmark

Unicycive Therapeutics (NASDAQ:UNCY) had its target price cut by Benchmark from $21.00 to $15.00 in a report issued on Monday morning,Benzinga reports. They currently have a speculative buy rating on the stock.

Several other brokerages have also recently commented on UNCY. Guggenheim cut their price target on shares of Unicycive Therapeutics from $46.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Westpark Capital began coverage on shares of Unicycive Therapeutics in a research note on Thursday, February 19th. They set a “buy” rating on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.67.

Unicycive Therapeutics Price Performance

Shares of NASDAQ:UNCY opened at $6.62 on Monday. The company’s 50-day moving average price is $6.66 and its two-hundred day moving average price is $5.86. Unicycive Therapeutics has a one year low of $3.71 and a one year high of $11.00. The stock has a market capitalization of $167.08 million, a PE ratio of -3.05 and a beta of 1.81.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.36). On average, analysts anticipate that Unicycive Therapeutics will post -0.23 earnings per share for the current fiscal year.

Institutional Trading of Unicycive Therapeutics

A number of institutional investors have recently bought and sold shares of UNCY. Lazard Asset Management LLC bought a new stake in Unicycive Therapeutics in the 2nd quarter valued at about $55,000. JPMorgan Chase & Co. boosted its holdings in Unicycive Therapeutics by 11,698.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after purchasing an additional 21,525 shares during the period. Citadel Advisors LLC bought a new stake in Unicycive Therapeutics in the 3rd quarter valued at about $182,000. Quadrature Capital Ltd bought a new stake in Unicycive Therapeutics in the 4th quarter valued at about $226,000. Finally, State Street Corp grew its holdings in shares of Unicycive Therapeutics by 19.0% during the 4th quarter. State Street Corp now owns 65,227 shares of the company’s stock worth $376,000 after purchasing an additional 10,400 shares in the last quarter. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.